AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00527748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Measuring Ankle Exerciser
Description: Stretching exercise performed 10 times per day, for six (6) weeks.
Study NCT03048019 — intervention group
Intervention type: DRUG
Intervention: Tirofiban
Description: Patients will receive Tirofiban during the PCI procedure
Study NCT03048019 — intervention group
Intervention type: DRUG
Intervention: Cangrelor
Description: Patients will receive Cangrelor during the PCI procedure
Study NCT01974687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
Study NCT01974687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to uprifosbuvir capsule administered by mouth.
Study NCT01974687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
Study NCT02868710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
Study NCT04282811 — intervention group
Intervention type: DRUG
Intervention: Venetoclax
Description: Patients treated with venetoclax-based regimens outside clinical trials in Italy
Study NCT01641666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
Study NCT01641666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b 1.5 mcg/kg/week
Description: Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
Study NCT01641666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
Study NCT04086134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fruit Products
Description: Fruit Products with the potential to improve constipation-related outcomes
Study NCT04086134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit Products
Description: Fruit Products with the potential to improve constipation-related outcomes
Study NCT03240055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
Study NCT03240055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: etomidate
Description: receive etomidate only
Study NCT04187690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jin-shui Huan-xian granule
Description: Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
Study NCT04187690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jin-shui Huan-xian granule placebo
Description: Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
Study NCT01141868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: online treatment for insomnia
Study NCT03796975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Pioglitazone and Metformin Tablets
Description: 15mg/500mg, oral, 2/day
Study NCT03796975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride Tablets
Description: Oral metformin 850mg, 2/day in the control group
Study NCT01818648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
Study NCT01818648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
Study NCT01502072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
Study NCT01502072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
Study NCT05134298 — intervention group
Intervention type: DRUG
Intervention: Piperacillin/tazobactam, Meropenem
Description: This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
Study NCT02767570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training; Altered Foot Progression Angle
Description: Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
Study NCT02767570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training; Consistent Foot Progression Angle
Description: Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
Study NCT03804372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
Study NCT03804372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
Study NCT03804372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
Study NCT00984815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZT-501
Description: Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
Study NCT03721068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9.GD2.CAR.IL-15 T-cells
Description: Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6
Study NCT03721068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
Study NCT03721068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
Study NCT00590070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
Study NCT00590070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprusside
Description: Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
Study NCT00590070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 33 cc of heparinized saline given in 2 minutes as slow bolus
Study NCT03403933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didrogyl
Description: Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study.
Study NCT02775747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma gel
Description: Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
Study NCT02775747 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
Study NCT04068727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Intervention
Description: After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
Study NCT00548691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Study NCT00548691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Study NCT01965483 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: once-weekly breast irradiation
Study NCT03241160 — intervention group
Intervention type: OTHER
Intervention: Chewing evaluation
Description: Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
Study NCT00782379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
Study NCT00782379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
Study NCT00782379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
Study NCT00782379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
Study NCT00782379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: 0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
Study NCT00782379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Patients to received unmanipulated PBSCs on Day 0
Study NCT00782379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: patients to receive unmanipulated PBSCs on day 0
Study NCT04481516 — intervention group
Intervention type: OTHER
Intervention: Yoga
Description: SKY Yoga
Study NCT04218760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]
Description: 1 tablet Isosorbide Mononitrate 60 mg administrated orally.
Study NCT04218760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
Study NCT00258713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.2, 0.3, or 0.4 mg/kg BID
Study NCT02854306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: With mindfulness programm
Study NCT02854306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Without mindfulness programm
Study NCT01686594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8-methoxypsoralen
Description: 8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
Study NCT00911963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222 or matching placebo
Description: capsule, oral, 4 doses once daily or twice daily, 3 days
Study NCT00911963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH-222 or matching placebo
Description: capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
Study NCT00911963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: subcutaneous injection, 180 μg, once weekly, 48 weeks
Study NCT00911963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
Study NCT02187822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m\^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
Study NCT02187822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy (FSRT)
Description: The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
Study NCT03420235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home monitoring program
Description: The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
Study NCT00802841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Supplied as 200 mg tablets
Study NCT03616093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Beet Shot
Description: Active supplement containing 6.2 mmol nitrate
Study NCT00802841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: Supplied as 100 mg and 400 mg tablets
Study NCT03342911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03342911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03342911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03279705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water jet channel
Description: The separate water jet channel was used for infusing water.
Study NCT03279705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accessory channel
Description: The accessory channel was used for infusing and/or suctioning water
Study NCT03279705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accessory channel
Description: The accessory channel was used for infusing and/or suctioning water
Study NCT03616093 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Placebo supplement containing negligible nitrate
Study NCT04351490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: Zinc gluconate capsule 15 mg x 2 per day during 2 months
Study NCT04351490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25-OH cholecalciferol
Description: 25-OH cholecalciferol drinkable solution 10 drops (2000 IU) per day during 2 months
Study NCT00377741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: 900mg po
Study NCT00862875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir or Glargine
Description: Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
Study NCT00862875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir or Glargine
Description: Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
Study NCT01973465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stool
Description: Implanting fecal matter via colonscope
Study NCT02176928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoPAP
Description: PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks).
Study NCT02176928 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PAP
Description: Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./
Study NCT00360555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: flibanserin
Description: flibanserin 25 mg b.i.d
Study NCT00360555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin 50mg
Description: flibanserin 50mg qhs/b.i.d.
Study NCT00360555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin 100mg
Description: flibanserin 50 mg b.i.d/100mg qhs
Study NCT00360555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo comparator
Study NCT01917734 — intervention group
Intervention type: OTHER
Intervention: Therapeutic feeding for children with SAM
Description: Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
Study NCT00163215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
Study NCT00739583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG 2% w/v and IPA 70% v/v
Description: Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds